Novo Nordisk A/S (NONOF)
OTCMKTS · Delayed Price · Currency is USD
38.74
-0.14 (-0.36%)
At close: Mar 10, 2026
Novo Nordisk Employees
As of December 31, 2025, Novo Nordisk had 69,505 total employees, including 68,794 full-time and 711 part-time employees. The number of employees decreased by 7,844 or -10.14% compared to the previous year.
Employees
69,505
Change
-7,844
Growth
-10.14%
Revenue / Employee
$702,650
Profits / Employee
$232,881
Market Cap
170.98B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% | 68,794 | 711 |
| Sep 30, 2025 | 78,554 | 6,674 | 9.28% | 78,554 | 0 |
| Jun 30, 2025 | 78,387 | 9,127 | 13.18% | 78,387 | 0 |
| Mar 31, 2025 | 77,406 | 11,391 | 17.26% | 77,406 | 0 |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% | 76,302 | 1,047 |
| Sep 30, 2024 | 71,880 | 10,468 | 17.05% | 71,880 | 0 |
| Jun 30, 2024 | 69,260 | 9,923 | 16.72% | 69,260 | 0 |
| Mar 31, 2024 | 66,015 | 8,926 | 15.64% | 66,015 | 0 |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% | 63,370 | 949 |
| Sep 30, 2023 | 61,412 | 8,716 | 16.54% | 61,412 | 0 |
| Jun 30, 2023 | 59,337 | 8,521 | 16.77% | 59,337 | 0 |
| Mar 31, 2023 | 57,089 | 7,794 | 15.81% | 57,089 | 0 |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% | 54,393 | 792 |
| Sep 30, 2022 | 52,696 | 5,714 | 12.16% | 52,696 | 0 |
| Jun 30, 2022 | 50,816 | 4,845 | 10.54% | 50,816 | 0 |
| Mar 31, 2022 | 49,295 | 4,138 | 9.16% | 49,295 | 0 |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% | 47,792 | 686 |
| Sep 30, 2021 | 46,982 | 2,656 | 5.99% | 46,982 | 0 |
| Jun 30, 2021 | 45,971 | 2,445 | 5.62% | 45,971 | 0 |
| Mar 31, 2021 | 45,157 | 1,999 | 4.63% | 45,157 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
Novo Nordisk News
- 12 hours ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO - GlobeNewsWire
- 16 hours ago - FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths - Forbes
- 16 hours ago - FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients - WSJ
- 17 hours ago - 2 Healthcare Stocks That Are Too Cheap to Ignore - The Motley Fool
- 19 hours ago - Novo Nordisk receives FDA warning regarding US inspection in 2025 - Reuters
- 20 hours ago - Novo Nordisk: Buying The Dip Before Volume Dominance - Seeking Alpha
- 23 hours ago - Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen. - Market Watch
- 1 day ago - Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock - The Motley Fool